Skip to content
Investors Dashboard
Contact
TwitterFacebookInstagramLinkedinYouTube
  • English
  • Spanish
TwitterFacebookInstagramLinkedinYouTube
  • English
  • Spanish
Pharmamar S.A
Pharmamar S.A.
Pharmamar S.APharmamar S.A
  • About PharmaMar
    • Senior Management
    • Management Team Oncology Unit
    • Management Team Virology Unit
    • Board of directors
    • Other Business
    • PharmaMar in the World
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • Products
    • YONDELIS®
    • Lurbinectedin
  • Science & Innovation
    • R&D and Innovation
    • Virology Unit
      • Our Vision
      • Molecular Pharmacodynamics
      • COVID-19, Clinical Development
      • COVID-19, Translational Strategy
    • Oncology Pipeline
    • Cofinanced Projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
    • Medical meeting presentations
  • Shareholders and Investors
    • Financial Information
      • Annual Reports
      • Interim financial information
      • Financial Statements (Zeltia)
      • Average Period of Payment to Suppliers
    • Notifications sent to CNMV
    • Share Information
      • Share Performance
      • Shares Outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt Obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
    • Contact
    • Merger PharmaMar-Zeltia
    • Política de Comunicación con Accionistas
  • Newsroom
    • Press Releases
    • Events calendar
    • Multimedia
      • Videos
      • Infographics
    • Medical meeting presentations
  • Careers
    • Benefits
    • Send us your CV
  • Corporate Bylaws
  • Regulation of the Shareholders’ Meeting of Pharma Mar, S.A.
  • Shareholder Agreements
  • Board of Directors
  • Board of Directors Regulation
  • Annual Report on Corporate Governance
  • Annual Director Remuneration Report
  • Board Committees
  • Internal Regulation Governing Conduct
  • About PharmaMar
    • Senior Management
    • Management Team Oncology Unit
    • Management Team Virology Unit
    • Board of directors
    • Other Business
    • PharmaMar in the World
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • Products
    • YONDELIS®
    • Lurbinectedin
  • Science & Innovation
    • R&D and Innovation
    • Virology Unit
      • Our Vision
      • Molecular Pharmacodynamics
      • COVID-19, Clinical Development
      • COVID-19, Translational Strategy
    • Oncology Pipeline
    • Cofinanced Projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
    • Medical meeting presentations
  • Shareholders and Investors
    • Financial Information
      • Annual Reports
      • Interim financial information
      • Financial Statements (Zeltia)
      • Average Period of Payment to Suppliers
    • Notifications sent to CNMV
    • Share Information
      • Share Performance
      • Shares Outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt Obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
    • Contact
    • Merger PharmaMar-Zeltia
    • Política de Comunicación con Accionistas
  • Newsroom
    • Press Releases
    • Events calendar
    • Multimedia
      • Videos
      • Infographics
    • Medical meeting presentations
  • Careers
    • Benefits
    • Send us your CV

Corporate Governance

You are here:
  1. Home
  2. Shareholders and Investors
  3. Corporate Governance
  4. Shareholder Agreements

Shareholders & Investors

  • Financial Information
  • Notifications sent to CNMV
  • Share Information
  • Debt Obligations
  • Presentations
  • Oncology Pipeline
  • Events calendar
  • General Shareholders Meetings
  • Corporate Governance
    • Corporate Bylaws >
    • General Shareholders’ Meeting Regulations >
    • Shareholder Agreements >
    • Board of Directors >
    • Board of Directors Regulation >
    • Annual Report on Corporate Governance >
    • Annual Director Remuneration Report >
    • Board Committees >
    • Internal Regulation Governing Conduct >
  • Contact
  • Merger PharmaMar-Zeltia
  • Política de Comunicación con Accionistas

Shareholder Agreements

The Company notified the CNMV through relevant fact number 252,480 the provision which constitutes a shareholders agreement included in the Subscription Agreement, described in the relevant fact number 252,144.

PHARMA MAR, S.A.
VAT: ESA-78267176

Avda. De los Reyes, 1
Pol. Ind. La Mina
28770 - Colmenar Viejo
Madrid, Spain
How to get here

34 91 846 6000
34 91 846 6001
pharmamar@pharmamar.com
If you wish to inform of an adverse event, please click here

Legal Notice
Privacy Policy
Cookies Policy

Copyright © 2021 PharmaMar - All Rights Reserved
 Dream-Theme — truly premium WordPress themes
Sobre PharmaMar
Go to Top
We use our own and third-party cookies in order to collect statistical information and to ensure the best experience on our site. If you want to accept them, click I agree.I agreeI do not acceptPrivacy policy
You can revoke your consent any time using the Revoke consent button.Revoke consent